[go: up one dir, main page]

ZA200809201B - Cocrystal of C-glycoside derivative and L-proline - Google Patents

Cocrystal of C-glycoside derivative and L-proline

Info

Publication number
ZA200809201B
ZA200809201B ZA2008/09201A ZA200809201A ZA200809201B ZA 200809201 B ZA200809201 B ZA 200809201B ZA 2008/09201 A ZA2008/09201 A ZA 2008/09201A ZA 200809201 A ZA200809201 A ZA 200809201A ZA 200809201 B ZA200809201 B ZA 200809201B
Authority
ZA
South Africa
Prior art keywords
cocrystal
proline
glycoside derivative
glycoside
derivative
Prior art date
Application number
ZA2008/09201A
Other languages
English (en)
Inventor
Masamichi Yuda
Keita Nakanishi
Ryota Shiraki
Daisuke Sasuga
Kenichi Onda
Masakazu Imamura
Original Assignee
Astellas Pharma Inc
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38563736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200809201(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of ZA200809201B publication Critical patent/ZA200809201B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2008/09201A 2006-04-05 2008-10-27 Cocrystal of C-glycoside derivative and L-proline ZA200809201B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006103711 2006-04-05
PCT/JP2007/057597 WO2007114475A1 (ja) 2006-04-05 2007-04-04 Ｃ－グリコシド誘導体とｌ－プロリンとの共結晶

Publications (1)

Publication Number Publication Date
ZA200809201B true ZA200809201B (en) 2009-12-30

Family

ID=38563736

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2008/09201A ZA200809201B (en) 2006-04-05 2008-10-27 Cocrystal of C-glycoside derivative and L-proline

Country Status (15)

Country Link
US (1) US8097592B2 (ru)
EP (1) EP2009010A4 (ru)
JP (1) JP5210154B2 (ru)
KR (2) KR20120025001A (ru)
CN (1) CN101443328B (ru)
AU (1) AU2007232763B2 (ru)
BR (1) BRPI0710581A2 (ru)
CA (1) CA2649022C (ru)
IL (1) IL194512A0 (ru)
MX (1) MX2008012705A (ru)
NO (1) NO20084659L (ru)
RU (1) RU2408595C2 (ru)
TW (1) TWI370818B (ru)
WO (1) WO2007114475A1 (ru)
ZA (1) ZA200809201B (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080990A1 (ja) * 2003-03-14 2004-09-23 Astellas Pharma Inc. Ｃ－グリコシド誘導体又はその塩
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
JPWO2008075736A1 (ja) 2006-12-21 2010-04-15 アステラス製薬株式会社 Ｃ−グリコシド誘導体の製造方法及びその合成中間体
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
KR101516677B1 (ko) * 2008-01-31 2015-05-04 고토부키 세이야쿠 가부시키가이샤 지방성 간 질환의 치료용 의약 조성물
DK2324002T3 (en) 2008-08-22 2016-12-19 Theracos Sub Llc Methods of making of sglt2 inhibitors
EP2334687B9 (en) * 2008-08-28 2012-08-08 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
RU2012121183A (ru) * 2009-10-23 2013-11-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения
KR101426180B1 (ko) 2009-11-02 2014-07-31 화이자 인코포레이티드 디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
CA2780939C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Bilayer tablet formulations
WO2011060255A1 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
CN102740839B (zh) 2009-11-13 2015-05-06 阿斯利康(瑞典)有限公司 立即释放片剂
NZ703128A (en) 2010-05-11 2016-04-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
AU2011295837B2 (en) 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
BR112013019026A2 (pt) 2011-02-01 2016-10-04 Astrazeneca Uk Ltd formulações farmacêuticas incluindo um composto amina
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2012116349A2 (en) * 2011-02-26 2012-08-30 Amplio Pharma, Llc Novel cocrystals of ezetimibe
EP2697218B1 (en) 2011-04-13 2016-05-25 Janssen Pharmaceutica NV Process for the preparation of compounds useful as inhibitors of sglt2
KR101841087B1 (ko) * 2011-04-22 2018-03-23 아스텔라스세이야쿠 가부시키가이샤 고형 의약 조성물
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
WO2012163990A1 (en) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
BR112014010574A2 (pt) 2011-10-31 2017-05-02 Scinopharm Taiwan Ltd formas cristalinas e não cristalinas de inibidores sglt2
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
ITMI20120586A1 (it) 2012-04-11 2013-10-12 Milano Politecnico Co-cristalli di 3-iodiopropinil butilcarbammato
RU2497804C1 (ru) * 2012-05-02 2013-11-10 Федеральное государственное бюджетное учреждение науки институт химии растворов им. Г.А. Крестова Российской академии наук Сокристаллическая форма 2-гидроксибензамида с 4-аминобензойной кислотой
US9145434B2 (en) * 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP2722327A1 (en) * 2012-10-22 2014-04-23 Quantum Genomics Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
CN111494357A (zh) 2013-12-17 2020-08-07 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
CN103626710A (zh) * 2013-12-20 2014-03-12 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法
WO2015095703A1 (en) * 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
ES2712860T3 (es) 2014-01-23 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales caninos
FI3721882T3 (fi) 2014-04-01 2024-09-24 Boehringer Ingelheim Vetmedica Gmbh Aineenvaihduntahäiriöiden hoito hevoseläimissä
KR101613488B1 (ko) 2014-06-18 2016-04-20 (주) 디엔디이 Mice 행사용 초대장 회답 통합관리시스템
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
EP3197429B1 (en) 2014-09-25 2024-05-22 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
BR112018003749B1 (pt) 2015-08-27 2023-10-31 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas líquidas compreendendo inibidores sglt-2, kit de peças e processo para a produção da composição farmacêutica líquida
EP3349762B1 (en) 2015-09-15 2021-08-25 Laurus Labs Limited Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
CN106924206A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 一种依格列净口服固体制剂及其制备方法
JP7429013B2 (ja) * 2017-12-11 2024-02-07 アーテロ バイオサイエンシズ，インコーポレイテッド カンナビジオールの新しい固体形態およびその使用
EP3784231A4 (en) * 2018-04-25 2022-05-11 Theracos Sub, LLC Methods of treating hypertension
KR102097250B1 (ko) 2019-11-09 2020-04-03 유니셀랩 주식회사 신규한 이프라글리플로진의 결정형, 이의 제조방법 또는 용도
AU2020394498A1 (en) 2019-11-28 2022-06-09 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors in the drying-off of non-human mammals
JP2023512958A (ja) * 2020-02-03 2023-03-30 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 小児期及び青年期のグルコース代謝の改善及び維持のための組成物及び方法
KR20220143732A (ko) 2020-02-17 2022-10-25 베링거잉겔하임베트메디카게엠베하 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
CN115916197A (zh) 2020-04-22 2023-04-04 拜耳公司 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合
KR102660615B1 (ko) 2020-10-28 2024-04-26 동방에프티엘(주) 이프라글리플로진의 신규 공결정 및 이의 제조 방법
CN113234028B (zh) * 2021-04-29 2022-08-26 上海大学 一种5-氟尿嘧啶与肌氨酸的共晶体及其制备方法与用途
JP2024525981A (ja) 2021-07-28 2024-07-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
AU2022319909A1 (en) 2021-07-28 2024-02-22 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
EP4456872A1 (en) 2021-12-30 2024-11-06 NewAmsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
KR20240044194A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
TW202500160A (zh) 2023-03-06 2025-01-01 德商百靈佳殷格翰維美迪加股份有限公司 用於遞送特別是包含一或多種ｓｇｌｔ—２抑制劑之液體醫藥組合物之系統及方法
TW202446389A (zh) 2023-04-24 2024-12-01 荷蘭商新阿姆斯特丹製藥公司 非晶形奧比特拉(obicetrapib)與sglt2抑制劑之組合
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
DE60209343T2 (de) * 2001-04-11 2006-10-26 Bristol-Myers Squibb Co. Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
WO2004080990A1 (ja) * 2003-03-14 2004-09-23 Astellas Pharma Inc. Ｃ－グリコシド誘導体又はその塩
EA015104B1 (ru) 2003-08-01 2011-06-30 Мицубиси Танабе Фарма Корпорейшн Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
NZ545133A (en) * 2003-09-04 2009-12-24 Cephalon Inc Modafinil compositions
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
JPWO2008075736A1 (ja) 2006-12-21 2010-04-15 アステラス製薬株式会社 Ｃ−グリコシド誘導体の製造方法及びその合成中間体

Also Published As

Publication number Publication date
CN101443328B (zh) 2012-07-25
EP2009010A1 (en) 2008-12-31
US8097592B2 (en) 2012-01-17
AU2007232763A1 (en) 2007-10-11
MX2008012705A (es) 2008-10-15
KR20120025001A (ko) 2012-03-14
CA2649022A1 (en) 2007-10-11
IL194512A0 (en) 2009-08-03
KR20090015912A (ko) 2009-02-12
RU2008143362A (ru) 2010-05-10
AU2007232763B2 (en) 2011-07-28
US20090143316A1 (en) 2009-06-04
RU2408595C2 (ru) 2011-01-10
TWI370818B (en) 2012-08-21
NO20084659L (no) 2009-01-02
JP5210154B2 (ja) 2013-06-12
CN101443328A (zh) 2009-05-27
JPWO2007114475A1 (ja) 2009-08-20
BRPI0710581A2 (pt) 2011-08-16
WO2007114475A1 (ja) 2007-10-11
EP2009010A4 (en) 2012-06-13
TW200811152A (en) 2008-03-01
KR101243039B1 (ko) 2013-03-20
CA2649022C (en) 2012-05-29

Similar Documents

Publication Publication Date Title
TWI370818B (en) Cocrystal of c-glycoside derivative and l-proline
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
IL195346A0 (en) Novel heterocyclic compound or salt thereof and intermediate thereof
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
EP2001338A4 (en) FURNITURE
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
IL192880A0 (en) Therapeutic uses of inhibitors of rtp801
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
IL196469A0 (en) New medical use of triazine derivatives
GB0610790D0 (en) Therapeutic uses of tomato extracts
GB0622472D0 (en) Novel heterocyclic derivatives
IL195061A0 (en) Crystalline forms of atorvastatin
EP2068903A4 (en) S-NITROSOTHIOL COMPOUNDS AND RELATED DERIVATIVES
EP1986997A4 (en) NEW CRYSTALLINE HEMI-CALCIUM FORM OF ATORVASTATIN
ZA200809112B (en) N-oxides of pyridylmethylpiperazine and -piperidine derivatives
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
GB0700179D0 (en) Use of epoxidised compounds
HU0500947D0 (en) Composition for treatment of paradontosis
TWM300229U (en) Improvement of lockset device
IL195722A0 (en) Therapeutic uses of inhibitors of rtp801l